Lisata Therapeutics, Inc.
LSTA
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trialā¦ read more
Healthcare
Biotechnology
27 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.15
Price+6.48%
$0.07
1Y
Price
Market Cap
$10.472m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$170k
-
1y CAGR-27.7%
3y CAGR-20.7%
5y CAGREarnings
-$16.351m
+1.4%
1y CAGR+7.5%
3y CAGR+21.0%
5y CAGREPS
-$1.86
+2.6%
1y CAGR+10.0%
3y CAGR+26.4%
5y CAGRBook Value
$10.672m
$14.059m
Assets$3.387m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$13.658m
+14.5%
1y CAGR+11.8%
3y CAGR+10.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company